Skip to main
PRCT

PRCT Stock Forecast & Price Target

PRCT Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 30%
Buy 50%
Hold 10%
Sell 10%
Strong Sell 0%

Bulls say

PROCEPT BioRobotics Corp is expected to see substantial growth, with anticipated procedure volumes increasing over 50% year-over-year in the second half of 2026, driven by successful commercial initiatives. The company demonstrated strong performance in its recent quarter with 58 new capital system placements, exceeding prior guidance and contributing to a 43% year-over-year sales increase to $83.3 million, surpassing both target and consensus projections. This robust demand, particularly within the benign prostatic hyperplasia (BPH) sector, along with expected increases in average selling prices, positions PROCEPT well for sustainable double-digit growth moving forward.

Bears say

PROCEPT BioRobotics Corp has announced fourth-quarter revenue that fell 19% below consensus expectations, coupled with a significant reduction in Fiscal Year 2026 sales guidance, indicating a troubling outlook for the company. The updated guidance projects sales of $390-410 million, which is 5% lower than market consensus, predominantly reflecting challenges in U.S. sales due to pressures on hospital profitability and reduced handpiece sales linked to the removal of bulk purchase discounts. This combination of disappointing financial performance and downward revisions has created significant volatility in the stock, leading to a negative sentiment among investors regarding the company's near-term prospects.

PRCT has been analyzed by 10 analysts, with a consensus rating of Buy. 30% of analysts recommend a Strong Buy, 50% recommend Buy, 10% suggest Holding, 10% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PROCEPT BioRobotics Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PROCEPT BioRobotics Corp (PRCT) Forecast

Analysts have given PRCT a Buy based on their latest research and market trends.

According to 10 analysts, PRCT has a Buy consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $37.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $37.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PROCEPT BioRobotics Corp (PRCT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.